Outcome of nucleos(t)ide analogue cessation in patients with treatment for prevention of or against hepatitis B virus reactivation.
Takanori SuzukiKentaro MatsuuraKenji UrakabeFumihiro OkumuraHayato KawamuraSatoshi SobueSho MatoyaTomokatsu MiyakiYoshihide KimuraDaisuke KatoAtsunori KusakabeYoshito TanakaAtsushi OzasaYoshihito NaguraKei FujiwaraShunsuke NojiriShinya HagiwaraShigeru KusumotoTakako InoueYasuhito TanakaHiromi KataokaPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2022)
We may be able to consider to cease NA therapy proactively in HBV carriers and resolved patients with non-hematological disease, if their primary diseases are under remission after completion of immunosuppressive therapy or chemotherapy. However, careful follow-up is necessary after stopping NA therapy. (250 words) This article is protected by copyright. All rights reserved.